Back

Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Antithrombotic therapy in acute coronary syndromes and PCI Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Roxana Mehran

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

6 More presentations in this session

Presentation thumbnail
Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention
Doctor A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors
Mr S. Rikken (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
Doctor S. Godtfredsen (Aalborg, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotic therapy in acute coronary syndromes and PCI

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Session
Long-term outcomes and innovations in revascularisation strategies
thumbnail
Congress Session
Revascularisation in chronic coronary syndrome
thumbnail
Congress Presentation
Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources